Serum concentrations of insulin-like growth factor-1, members of the TGF-beta superfamily and follistatin do not reflect different stages of dynapenia and sarcopenia in elderly women

Experimental Gerontology

Volumn 64, Issue , 2015, Pages 35-45

  Hofmann, Marlene ^a   Halper, Barbara ^a   Oesen, Stefan ^a   Franzke, Bernhard ^a   Stuparits, Petra ^a   Tschan, Harald ^a   Bachl, Norbert ^a   Strasser, Eva Maria ^b   Quittan, Michael ^b   Ploder, Martin ^c   Wagner, Karl Heinz ^a   Wessner, Barbara ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b Social Medical Center South   (Austria)

^c Department of Surgery   (Austria)

Author keywords

Dynapenia; Serum biomarkers; Skeletal muscle atrophy; TGF beta superfamily; Vienna active ageing study (VAAS)

Indexed keywords

ACTIVIN A; BONE MORPHOGENETIC PROTEIN 15; FOLLISTATIN; MYOSTATIN; SOMATOMEDIN C; ACTIVIN; BIOLOGICAL MARKER; GDF15 PROTEIN, HUMAN; GROWTH DIFFERENTIATION FACTOR 15; MSTN PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

AGE; AGED; ARTICLE; BODY COMPOSITION; DISEASE ASSOCIATION; DISEASE SEVERITY; DYNAPENIA; FAT MASS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MUSCLE DISEASE; MUSCLE MASS; PHYSICAL PERFORMANCE; PROTEIN BLOOD LEVEL; SARCOPENIA; ADULT; AUSTRIA; BLOOD; COMORBIDITY; MUSCULAR ATROPHY; PHYSICAL EXAMINATION; REGRESSION ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ACTIVINS; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AUSTRIA; BIOMARKERS; BODY COMPOSITION; COMORBIDITY; FEMALE; FOLLISTATIN; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MUSCULAR ATROPHY; MYOSTATIN; PHYSICAL EXAMINATION; REGRESSION ANALYSIS; SARCOPENIA; TGF-BETA SUPERFAMILY PROTEINS; YOUNG ADULT;

EID: 84923047596     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2015.02.008     Document Type: Article

References (51)

1. Baccarelli A., Morpurgo P.S., Corsi A., Vaghi I., Fanelli M., Cremonesi G., Vaninetti S., Beck-Peccoz P., Spada A. Activin A serum levels and aging of the pituitary-gonadal axis: a cross-sectional study in middle-aged and elderly healthy subjects. Exp. Gerontol. 2001, 36:1403-1412. (doi: S0531-5565(01)00117-6).
2. Barbieri M., Ferrucci L., Ragno E., Corsi A., Bandinelli S., Bonafe M., Olivieri F., Giovagnetti S., Franceschi C., Guralnik J.M., Paolisso G. Chronic inflammation and the effect of IGF-I on muscle strength and power in older persons. Am. J. Physiol. Endocrinol. Metab. 2003, 284:E481-E487. 10.1152/ajpendo.00319.2002.
3. Blain H., Jaussent A., Beziat S., Dupuy A.M., Bernard P.L., Mariano-Goulart D., Cristol J.P., Sultan C., Picot M.C. Low serum IL-6 is associated with high 6-minute walking performance in asymptomatic women aged 20 to 70years. Exp. Gerontol. 2012, 47:143-148. 10.1016/j.exger.2011.11.008.
4. Bloch S.A., Lee J.Y., Wort S.J., Polkey M.I., Kemp P.R., Griffiths M.J. Sustained elevation of circulating growth and differentiation factor-15 and a dynamic imbalance in mediators of muscle homeostasis are associated with the development of acute muscle wasting following cardiac surgery. Crit. Care Med. 2013, 41:982-989. 10.1097/CCM.0b013e318274671b.
5. Bowser M., Herberg S., Arounleut P., Shi X., Fulzele S., Hill W.D., Isales C.M., Hamrick M.W. Effects of the activin A-myostatin-follistatin system on aging bone and muscle progenitor cells. Exp. Gerontol. 2013, 48:290-297. 10.1016/j.exger.2012.11.004.
6. Brandt C., Nielsen A.R., Fischer C.P., Hansen J., Pedersen B.K., Plomgaard P. Plasma and muscle myostatin in relation to type 2 diabetes. PLoS One 2012, 7:e37236. 10.1371/journal.pone.0037236.
7. Cappola A.R., Bandeen-Roche K., Wand G.S., Volpato S., Fried L.P. Association of IGF-I levels with muscle strength and mobility in older women. J. Clin. Endocrinol. Metab. 2001, 86:4139-4146. 10.1210/jcem.86.9.7868.
8. Cesari M., Kritchevsky S.B., Newman A.B., Simonsick E.M., Harris T.B., Penninx B.W., Brach J.S., Tylavsky F.A., Satterfield S., Bauer D.C., Rubin S.M., Visser M., Pahor M. Added value of physical performance measures in predicting adverse health-related events: results from the Health, Aging and Body Composition Study. J. Am. Geriatr. Soc. 2009, 57:251-259. 10.1111/j.1532-5415.2008.02126.x.
9. Cesari M., Fielding R.A., Pahor M., Goodpaster B., Hellerstein M., van Kan G.A., Anker S.D., Rutkove S., Vrijbloed J.W., Isaac M., Rolland Y., M'Rini C., Aubertin-Leheudre M., Cedarbaum J.M., Zamboni M., Sieber C.C., Laurent D., Evans W.J., Roubenoff R., Morley J.E., Vellas B. Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia. J. Cachex. Sarcopenia Muscle 2012, 3:181-190. 10.1007/s13539-012-0078-2.
10. Chen J.L., Walton K.L., Al-Musawi S.L., Kelly E.K., Qian H., La M., Lu L., Lovrecz G., Ziemann M., Lazarus R., El-Osta A., Gregorevic P., Harrison C.A. Development of novel activin-targeted therapeutics. Mol. Ther. 2014, 10.1038/mt.2014.221.
11. Chen J.L., Walton K.L., Winbanks C.E., Murphy K.T., Thomson R.E., Makanji Y., Qian H., Lynch G.S., Harrison C.A., Gregorevic P. Elevated expression of activins promotes muscle wasting and cachexia. FASEB J. 2014, 10.1096/fj.13-245894.
12. Cruz-Jentoft A.J., Baeyens J.P., Bauer J.M., Boirie Y., Cederholm T., Landi F., Martin F.C., Michel J.P., Rolland Y., Schneider S.M., Topinkova E., Vandewoude M., Zamboni M. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010, 39:412-423. 10.1093/ageing/afq034.
13. Drey M., Sieber C.C., Bauer J.M., Uter W., Dahinden P., Fariello R.G., Vrijbloed J.W., FiAT intervention group C-terminal agrin fragment as a potential marker for sarcopenia caused by degeneration of the neuromuscular junction. Exp. Gerontol. 2013, 48:76-80. 10.1016/j.exger.2012.05.021.
14. Eggers K.M., Kempf T., Wallentin L., Wollert K.C., Lind L. Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community-dwelling elderly individuals. Clin. Chem. 2013, 59:1091-1098. 10.1373/clinchem.2012.201210.
15. Frystyk J. Exercise and the growth hormone-insulin-like growth factor axis. Med. Sci. Sports Exerc. 2010, 42:58-66. 10.1249/MSS.0b013e3181b07d2d.
16. Goldspink G., Wessner B., Tschan H., Bachl N. Growth factors, muscle function, and doping. Endocrinol. Metab. Clin. North Am. 2010, 39(xi):169-181. 10.1016/j.ecl.2009.11.001.
17. Goodpaster B.H., Park S.W., Harris T.B., Kritchevsky S.B., Nevitt M., Schwartz A.V., Simonsick E.M., Tylavsky F.A., Visser M., Newman A.B. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J. Gerontol. A Biol. Sci. Med. Sci. 2006, 61:1059-1064.
18. Han H.Q., Zhou X., Mitch W.E., Goldberg A.L. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int. J. Biochem. Cell Biol. 2013, 45:2333-2347. 10.1016/j.biocel.2013.05.019.
19. Hansen J., Brandt C., Nielsen A.R., Hojman P., Whitham M., Febbraio M.A., Pedersen B.K., Plomgaard P. Exercise induces a marked increase in plasma follistatin: evidence that follistatin is a contraction-induced hepatokine. Endocrinology 2011, 152:164-171. 10.1210/en.2010-0868.
20. Hittel D.S., Berggren J.R., Shearer J., Boyle K., Houmard J.A. Increased secretion and expression of myostatin in skeletal muscle from extremely obese women. Diabetes 2009, 58:30-38. 10.2337/db08-0943.
21. Janssen I., Heymsfield S.B., Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J. Am. Geriatr. Soc. 2002, 50:889-896.
22. Janssen I., Baumgartner R.N., Ross R., Rosenberg I.H., Roubenoff R. Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. Am. J. Epidemiol. 2004, 159:413-421.
23. Jones C.J., Rikli R.E., Beam W.C. A 30-s chair-stand test as a measure of lower body strength in community-residing older adults. Res. Q. Exerc. Sport 1999, 70:113-119.
24. Khan A.S., Sane D.C., Wannenburg T., Sonntag W.E. Growth hormone, insulin-like growth factor-1 and the aging cardiovascular system. Cardiovasc. Res. 2002, 54:25-35. (doi: S0008636301005338).
25. Kollias H.D., McDermott J.C. Transforming growth factor-beta and myostatin signaling in skeletal muscle. J. Appl. Physiol. (1985) 2008, 104:579-587.
26. Lakshman K.M., Bhasin S., Corcoran C., Collins-Racie L.A., Tchistiakova L., Forlow S.B., St Ledger K., Burczynski M.E., Dorner A.J., Lavallie E.R. Measurement of myostatin concentrations in human serum: circulating concentrations in young and older men and effects of testosterone administration. Mol. Cell. Endocrinol. 2009, 302:26-32. 10.1016/j.mce.2008.12.019.
27. Lee S.J., Lee Y.S., Zimmers T.A., Soleimani A., Matzuk M.M., Tsuchida K., Cohn R.D., Barton E.R. Regulation of muscle mass by follistatin and activins. Mol. Endocrinol. 2010, 24:1998-2008. 10.1210/me.2010-0127.
28. LeRoith D., Yakar S. Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat. Clin. Pract. Endocrinol. Metab. 2007, 3:302-310. 10.1038/ncpendmet0427.
29. Loria P., Petraglia F., Concari M., Bertolotti M., Martella P., Luisi S., Grisolia C., Foresta C., Volpe A., Genazzani A.R., Carulli N. Influence of age and sex on serum concentrations of total dimeric activin A. Eur. J. Endocrinol. 1998, 139:487-492.
30. Manini T.M., Clark B.C. Dynapenia and aging: an update. J. Gerontol. A Biol. Sci. Med. Sci. 2012, 67:28-40. 10.1093/gerona/glr010.
31. Marzetti E., Calvani R., Lorenzi M., Marini F., D'Angelo E., Martone A.M., Celi M., Tosato M., Bernabei R., Landi F. Serum levels of C-terminal agrin fragment (CAF) are associated with sarcopenia in older hip fractured patients. Exp. Gerontol. 2014, 10.1016/j.exger.2014.10.003.
32. Mijnarends D.M., Meijers J.M., Halfens R.J., ter Borg S., Luiking Y.C., Verlaan S., Schoberer D., Cruz Jentoft A.J., van Loon L.J., Schols J.M. Validity and reliability of tools to measure muscle mass, strength, and physical performance in community-dwelling older people: a systematic review. J. Am. Med. Dir. Assoc. 2013, 14:170-178. 10.1016/j.jamda.2012.10.009.
33. Obermayr R.P., Mayerhofer L., Knechtelsdorfer M., Mersich N., Huber E.R., Geyer G., Tragl K.H. The age-related down-regulation of the growth hormone/insulin-like growth factor-1 axis in the elderly male is reversed considerably by donepezil, a drug for Alzheimer's disease. Exp. Gerontol. 2005, 40:157-163. 10.1016/j.exger.2004.11.001.
34. Ratkevicius A., Joyson A., Selmer I., Dhanani T., Grierson C., Tommasi A.M., DeVries A., Rauchhaus P., Crowther D., Alesci S., Yaworsky P., Gilbert F., Redpath T.W., Brady J., Fearon K.C., Reid D.M., Greig C.A., Wackerhage H. Serum concentrations of myostatin and myostatin-interacting proteins do not differ between young and sarcopenic elderly men. J. Gerontol. A Biol. Sci. Med. Sci. 2011, 66:620-626. 10.1093/gerona/glr025.
35. Rosenberg I.H. Sarcopenia: origins and clinical relevance. J. Nutr. 1997, 127:990S-991S.
36. Roubenoff R., Baumgartner R.N., Harris T.B., Dallal G.E., Hannan M.T., Economos C.D., Stauber P.M., Wilson P.W., Kiel D.P. Application of bioelectrical impedance analysis to elderly populations. J. Gerontol. A Biol. Sci. Med. Sci. 1997, 52:M129-M136.
37. Sayer A.A., Robinson S.M., Patel H.P., Shavlakadze T., Cooper C., Grounds M.D. New horizons in the pathogenesis, diagnosis and management of sarcopenia. Age Ageing 2013, 42:145-150. 10.1093/ageing/afs191.
38. Schulte J.N., Yarasheski K.E. Effects of resistance training on the rate of muscle protein synthesis in frail elderly people. Int. J. Sport Nutr. Exerc. Metab. 2001, 11(Suppl):S111-S118.
39. Steffen T.M., Hacker T.A., Mollinger L. Age- and gender-related test performance in community-dwelling elderly people: six-minute walk test, Berg balance scale, timed up & go test, and gait speeds. Phys. Ther. 2002, 82:128-137.
40. Taekema D.G., Ling C.H., Blauw G.J., Meskers C.G., Westendorp R.G., de Craen A.J., Maier A.B. Circulating levels of IGF1 are associated with muscle strength in middle-aged- and oldest-old women. Eur. J. Endocrinol. 2011, 164:189-196. 10.1530/EJE-10-0703.
41. Tsai V.W., Husaini Y., Manandhar R., Lee-Ng K.K., Zhang H.P., Harriott K., Jiang L., Lin S., Sainsbury A., Brown D.A., Breit S.N. Anorexia/cachexia of chronic diseases: a role for the TGF-beta family cytokine MIC-1/GDF15. J. Cachex. Sarcopenia Muscle 2012, 3:239-243. 10.1007/s13539-012-0082-6.
42. Ueland T., Aukrust P., Aakhus S., Smith C., Endresen K., Birkeland K.I., Gullestad L., Johansen O.E. Activin A and cardiovascular disease in type 2 diabetes mellitus. Diabetes Vasc. Dis. Res. 2012, 9:234-237. 10.1177/1479164111431171.
43. Vamvini M.T., Aronis K.N., Chamberland J.P., Mantzoros C.S. Energy deprivation alters in a leptin- and cortisol-independent manner circulating levels of activin A and follistatin but not myostatin in healthy males. J. Clin. Endocrinol. Metab. 2011, 96:3416-3423. 10.1210/jc.2011-1665.
44. Volpato S., Bianchi L., Cherubini A., Landi F., Maggio M., Savino E., Bandinelli S., Ceda G.P., Guralnik J.M., Zuliani G., Ferrucci L. Prevalence and clinical correlates of sarcopenia in community-dwelling older people: application of the EWGSOP definition and diagnostic algorithm. J. Gerontol. A Biol. Sci. Med. Sci. 2014, 69:438-446. 10.1093/gerona/glt149.
45. Werle S., Goldhahn J., Drerup S., Simmen B.R., Sprott H., Herren D.B. Age- and gender-specific normative data of grip and pinch strength in a healthy adult Swiss population. J. Hand Surg. Eur. 2009, 34:76-84. 10.1177/1753193408096763.
46. White T.A., Lebrasseur N.K. Myostatin and sarcopenia: opportunities and challenges - a mini-review. Gerontology 2014, 10.1159/000356740.
47. Windelinckx A., De Mars G., Huygens W., Peeters M.W., Vincent B., Wijmenga C., Lambrechts D., Delecluse C., Roth S.M., Metter E.J., Ferrucci L., Aerssens J., Vlietinck R., Beunen G.P., Thomis M.A. Comprehensive fine mapping of chr12q12-14 and follow-up replication identify activin receptor 1B (ACVR1B) as a muscle strength gene. Eur. J. Hum. Genet. 2011, 19:208-215. 10.1038/ejhg.2010.173.
48. Wintgens K.F., Dschietzig T., Stoeva S., Paulsson M., Armbruster F.P. Plasma myostatin measured by a competitive ELISA using a highly specific antiserum. Clin. Chim. Acta 2012, 413:1288-1294. 10.1016/j.cca.2012.04.023.
49. Yaden B.C., Wang Y.X., Wilson J.M., Culver A.E., Milner A., Datta-Mannan A., Shetler P., Croy J.E., Dai G., Krishnan V. Inhibition of activin A ameliorates skeletal muscle injury and rescues contractile properties by inducing efficient remodeling in female mice. Am. J. Pathol. 2014, 184:1152-1166. 10.1016/j.ajpath.2013.12.029.
50. Yarasheski K.E., Bhasin S., Sinha-Hikim I., Pak-Loduca J., Gonzalez-Cadavid N.F. Serum myostatin-immunoreactive protein is increased in 60-92year old women and men with muscle wasting. J. Nutr. Health Aging 2002, 6:343-348.
51. Zhu J., Li Y., Lu A., Gharaibeh B., Ma J., Kobayashi T., Quintero A.J., Huard J. Follistatin improves skeletal muscle healing after injury and disease through an interaction with muscle regeneration, angiogenesis, and fibrosis. Am. J. Pathol. 2011, 179:915-930. 10.1016/j.ajpath.2011.04.008.